Advertisement

Insights


My Treatment Approach: Relapsed/Refractory Follicular Lymphoma

October 27th 2022

Brian Hill, MD, PhD and Lori Leslie, MD, discuss their respective treatment approaches to relapsed/refractory follicular lymphoma (R/R FL), sharing patient cases, reviewing treatment options for patients with the disease, and providing clinical advice for community-based oncologists.

Analysis of Hepatotoxicity Associated With TKIs in Solid Tumors

October 18th 2022

Tanios S. Bekaii-Saab, MD, analyzes the common adverse events (AEs) associated with tyrosine kinase inhibitors (TKIs) across solid tumors, with a special focus on hepatotoxicity and the clinical implications of this AE for future clinical studies of TKIs in combination with immune checkpoint inhibitors.

Addressing Disparities and Practicing Multicultural Care in Myeloma

October 13th 2022

Joseph Mikhael, MD, and Craig Cole, MD, discuss the substantial disparities in incidence and survival rates between patient populations with multiple myeloma, especially between Black and white Americans.

Integrating Molecular Testing into Decision Making in NSCLC

October 12th 2022

A panel of oncologists share insights on molecular testing in non-small cell lung cancer (NSCLC) and how they integrate and interpret the results to optimize treatment selection for their patients.

Sponsored in part by Takeda Oncology. Content independently developed by OncLive.

My Treatment Approach: Metastatic Endometrial Cancer

October 11th 2022

Expert oncologists center discussion on a clinical scenario to highlight optimal treatment strategies in metastatic endometrial cancer (mEC).

My Treatment Approach: Metastatic Triple-Negative Breast Cancer

September 13th 2022

Expert oncologists center discussion on a clinical scenario to highlight optimal treatment strategies in metastatic triple-negative breast cancer.

Evolving Approaches in the Management of Neuroendocrine Tumor-Associated Carcinoid Syndrome

September 13th 2022

Satya (Nanu) Das, MD, MSCI, Rodney Pommier, MD, and Jerome Zacks, MD, discuss how patients with neuroendocrine tumors progress to carcinoid syndrome and carcinoid heart disease, and how strategies for management have changed after key clinical trial data.

Funding provided by TerSera Therapeutics LLC. Content independently developed by OncLive.

My Treatment Approach: Recent Advances in the Treatment of Multiple Myeloma in Early Relapse

August 18th 2022

Brea Lipe, MD, and Peter Forsberg, MD, discuss updates in the treatment of R/R multiple myeloma, and present two hypothetical patient profiles to show how recent data can be incorporated into clinical practice.

Recent Advances in Molecular Biomarkers in Multiple Myeloma

August 10th 2022

Dr Shaji Kumar and Dr Jonathan Kaufman discuss the evolving role of biomarkers in multiple myeloma.

Tools to Guide Treatment Decisions in Breast Cancer

August 5th 2022

Mark Pegram, MD, and Lee Schwartzberg, MD, FACP, have a discussion on the management of early-stage hormone-receptor-positive breast cancer and the tools available to help inform treatment decisions.

My Treatment Approach: Metastatic Triple-Negative Breast Cancer

July 18th 2022

Expert oncologists center discussion on a clinical scenario to highlight optimal treatment strategies in metastatic triple-negative breast cancer.

Updates in Treatment and Management of Chemotherapy-induced Myelosuppression

July 8th 2022

Two experts in the management of extensive-stage small cell lung cancer provide an overview of chemotherapy-induced myelosuppression and share key insights into the myeloprotective benefit of the CDK4/6 inhibitor trilaciclib.

Tamibarotene in Newly Diagnosed Acute Myeloid Leukemia (AML)

June 17th 2022

Dr Daniel Pollyea comments on the potential use of tamibarotene in patients that are newly diagnosed with acute myeloid leukemia (AML).

Tamibarotene in Higher-Risk Myelodysplastic Syndrome (MDS)

June 17th 2022

Dr Gustavo Rivero discusses how and where tamibarotene might fit into the treatment landscape for patients with higher-risk myelodysplastic syndrome (MDS).

Inside the Clinic: Basal Cell Carcinoma Treatment Advances

June 16th 2022

Jennifer Atlas, MD, and Shahab Babakoohi, MD, discuss advances in the treatment of patients with basal cell carcinoma and their treatment approaches to clinical scenarios based on updated data.

My Treatment Approach: Targeting HER2 in Metastatic Colorectal Cancer

June 15th 2022

An expert oncologist and pathologist discuss molecular testing in metastatic colorectal cancer and the current and upcoming options for HER2-targeted therapies.

Recent Updates on CDK4/6 Inhibitors for HR-Positive, HER2-Negative Metastatic Breast Cancer

June 15th 2022

Expert perspectives on recent evolutions with CDK4/6 inhibitors in the HR+, HER2- metastatic breast cancer treatment landscape.

My Treatment Approach: The Evolving Treatment Landscape of Esophageal Squamous Cell Carcinoma

June 8th 2022

Expert provides an overview of esophageal squamous cell carcinoma (ESCC), discusses several key updates to the treatment landscape, and elucidates how clinicians can improve patient outcomes by applying data from the treatment algorithm.

My Treatment Approach: Acute Myeloid Leukemia (AML)

May 26th 2022

Richard Stone, MD, and Eunice Wang, MD, discuss recent advances in the treatment of newly-diagnosed acute myeloid leukemia and its impact on clinical practice.

My Treatment Approach: Bispecifics in Multiple Myeloma: Translating Evidence to Clinical Practice

May 26th 2022

Centering discussion on real-world patient scenarios, expert hematologist-oncologists review recent treatment advances in multiple myeloma with a focus on bispecifics and their impact on clinical practice.

Advertisement
Advertisement